268 related articles for article (PubMed ID: 26449615)
1. Low-dose gemcitabine induces major histocompatibility complex class I-related chain A/B expression and enhances an antitumor innate immune response in pancreatic cancer.
Miyashita T; Miki K; Kamigaki T; Makino I; Nakagawara H; Tajima H; Takamura H; Kitagawa H; Fushida S; Ahmed AK; Duncan MD; Harmon JW; Ohta T
Clin Exp Med; 2017 Feb; 17(1):19-31. PubMed ID: 26449615
[TBL] [Abstract][Full Text] [Related]
2. [Gemcitabine augments major histocompatibility complex class I-related chain A expression in pancreatic cancer].
Miyashita T; Tajima H; Shoji M; Nakanuma S; Sakai S; Makino I; Hayashi H; Nakagawara H; Takamura H; Kitagawa H; Ohta T
Gan To Kagaku Ryoho; 2013 Nov; 40(12):1600-2. PubMed ID: 24393861
[TBL] [Abstract][Full Text] [Related]
3. Low-dose valproic acid with low-dose gemcitabine augments MHC class I-related chain A/B expression without inducing the release of soluble MHC class I-related chain A/B.
Miyashita T; Miki K; Kamigaki T; Makino I; Tajima H; Nakanuma S; Hayashi H; Takamura H; Fushida S; Ahmed AK; Harmon JW; Ohta T
Oncol Lett; 2017 Nov; 14(5):5918-5926. PubMed ID: 29113227
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex class I-related chain A/B (MICA/B) expression in tumor tissue and serum of pancreatic cancer: role of uric acid accumulation in gemcitabine-induced MICA/B expression.
Xu X; Rao GS; Groh V; Spies T; Gattuso P; Kaufman HL; Plate J; Prinz RA
BMC Cancer; 2011 May; 11():194. PubMed ID: 21605422
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial cytotoxicity of gemcitabine and cytokine-activated killer cells in hepatocellular carcinoma via the NKG2D-MICA/B system.
Morisaki T; Onishi H; Koya N; Kiyota A; Tanaka H; Umebayashi M; Ogino T; Nagamatsu I; Katano M
Anticancer Res; 2011 Jul; 31(7):2505-10. PubMed ID: 21873167
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine enhances Wilms' tumor gene WT1 expression and sensitizes human pancreatic cancer cells with WT1-specific T-cell-mediated antitumor immune response.
Takahara A; Koido S; Ito M; Nagasaki E; Sagawa Y; Iwamoto T; Komita H; Ochi T; Fujiwara H; Yasukawa M; Mineno J; Shiku H; Nishida S; Sugiyama H; Tajiri H; Homma S
Cancer Immunol Immunother; 2011 Sep; 60(9):1289-97. PubMed ID: 21607557
[TBL] [Abstract][Full Text] [Related]
7. Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity.
Märten A; von Lilienfeld-Toal M; Büchler MW; Schmidt J
Int J Cancer; 2006 Nov; 119(10):2359-65. PubMed ID: 16929491
[TBL] [Abstract][Full Text] [Related]
8. Expression of major histocompatibility complex class I-related chain A/B (MICA/B) in pancreatic carcinoma.
Dambrauskas Z; Svensson H; Joshi M; Hyltander A; Naredi P; Iresjö BM
Int J Oncol; 2014 Jan; 44(1):99-104. PubMed ID: 24173243
[TBL] [Abstract][Full Text] [Related]
9. Ethanol-dependent expression of the NKG2D ligands MICA/B in human cell lines and leukocytes.
Streltsova MA; Klinkova AV; Kuchukova AA; Kadin AY; Kanevskiy LM; Kovalenko EI
Biochem Cell Biol; 2017 Apr; 95(2):280-288. PubMed ID: 28177768
[TBL] [Abstract][Full Text] [Related]
10. DNT cell inhibits the growth of pancreatic carcinoma via abnormal expressions of NKG2D and MICA in vivo.
Xu H; Zhu XX; Chen J
Biochem Biophys Res Commun; 2016 Jan; 469(2):145-50. PubMed ID: 26616050
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological significance of major histocompatibility complex class I-related chain a and B expression in thyroid cancer.
Xu X; Rao G; Gaffud MJ; Ding HG; Maki G; Klingemann HG; Groh V; Spies T; Caillat-Zucman S; Gattuso P; Plate J; Prinz RA
J Clin Endocrinol Metab; 2006 Jul; 91(7):2704-12. PubMed ID: 16621903
[TBL] [Abstract][Full Text] [Related]
12. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of the HDAC/Suv39/G9a pathway restores the expression of DNA damage-dependent major histocompatibility complex class I-related chain A and B in cancer cells.
Nakajima NI; Niimi A; Isono M; Oike T; Sato H; Nakano T; Shibata A
Oncol Rep; 2017 Aug; 38(2):693-702. PubMed ID: 28677817
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of gemcitabine by polysaccharide-induced NK cell activation and immune cytotoxicity reduction in vitro/vivo.
Xie X; Zhou Y; Wang X; Guo J; Li J; Fan H; Dou J; Shen B; Zhou C
Carbohydr Polym; 2017 Oct; 173():360-371. PubMed ID: 28732877
[TBL] [Abstract][Full Text] [Related]
15. Proapoptotic and antiapoptotic proteins of the Bcl-2 family regulate sensitivity of pancreatic cancer cells toward gemcitabine and T-cell-mediated cytotoxicity.
Bauer C; Hees C; Sterzik A; Bauernfeind F; Mak'Anyengo R; Duewell P; Lehr HA; Noessner E; Wank R; Trauzold A; Endres S; Dauer M; Schnurr M
J Immunother; 2015 Apr; 38(3):116-26. PubMed ID: 25751501
[TBL] [Abstract][Full Text] [Related]
16. NKG2D-directed cytokine-activated killer lymphocyte therapy combined with gemcitabine for patients with chemoresistant metastatic solid tumors.
Morisaki T; Hirano T; Koya N; Kiyota A; Tanaka H; Umebayashi M; Onishi H; Katano M
Anticancer Res; 2014 Aug; 34(8):4529-38. PubMed ID: 25075096
[TBL] [Abstract][Full Text] [Related]
17. The histone methyltransferase G9a as a therapeutic target to override gemcitabine resistance in pancreatic cancer.
Pan MR; Hsu MC; Luo CW; Chen LT; Shan YS; Hung WC
Oncotarget; 2016 Sep; 7(38):61136-61151. PubMed ID: 27531902
[TBL] [Abstract][Full Text] [Related]
18. CD20-Specific Immunoligands Engaging NKG2D Enhance γδ T Cell-Mediated Lysis of Lymphoma Cells.
Peipp M; Wesch D; Oberg HH; Lutz S; Muskulus A; van de Winkel JGJ; Parren PWHI; Burger R; Humpe A; Kabelitz D; Gramatzki M; Kellner C
Scand J Immunol; 2017 Oct; 86(4):196-206. PubMed ID: 28708284
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of the immunostimulatory MHC class I chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer.
Duan X; Deng L; Chen X; Lu Y; Zhang Q; Zhang K; Hu Y; Zeng J; Sun W
Med Oncol; 2011 Jun; 28(2):466-74. PubMed ID: 20354827
[TBL] [Abstract][Full Text] [Related]
20. The fatty-acid amide hydrolase inhibitor URB597 inhibits MICA/B shedding.
Sekiba K; Otsuka M; Seimiya T; Tanaka E; Funato K; Miyakawa Y; Koike K
Sci Rep; 2020 Sep; 10(1):15556. PubMed ID: 32968163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
